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Available online xxxxBackground: Circulating B-type natriuretic peptide (BNP) is widely accepted as a diagnostic and risk assess-
ment biomarker of cardiac function. Studies suggest that there are signiﬁcant differences inmeasured concentra-
tions among different commercial BNP immunoassays. The purpose of our study was to compare BNP-related
proteins to determine a form that could be used as a common calibrator to improve the comparability of com-
mercial BNP immunoassay results.
Methods: BNPwasmeasured in 40 EDTA-plasma samples from acute and chronic heart failure patients using
ﬁve commercial BNP assays: Alere Triage, Siemens Centaur XP, Abbott I-STAT, Beckman Access2 and ET
Healthcare Pylon. In parallel with internal calibrators from each manufacturer, six preparations containing BNP
1–32 motif a) synthetic BNP, b) recombinant BNP (E. coli), c) recombinant nonglycosylated proBNP (E. coli),
d) recombinant His-tagged (N-terminal) nonglycosylated proBNP (E. coli), e) recombinant glycosylated proBNP
(HEK cells), and f) recombinant glycosylated proBNP (CHO cells) were also used as external calibrators for each
assay.
Results: Using the internal standards provided by manufacturers and for ﬁve of six external calibrators, up
to 3.6-fold differences (mean 1.9-fold) were observed between BNP immunoassays (mean between-assay CV
24.5–47.2%). A marked reduction of the between-assay variability was achieved, when glycosylated proBNP
expressed in HEK cells was used as the common calibrator for all assays (mean between-assay CV 14.8%).
Conclusions:Our data suggest that recombinant glycosylated proBNP could serve as a common calibrator for
BNP immunoassays to reduce between-assay variability and achieve better comparability of BNP concentrations
of commercial BNP immunoassays.







B-typenatriuretic peptide (BNP) is a 32 amino acid circulating peptide
hormone produced by myocardium [1–3]. BNP is widely accepted as
both a clinical useful and cost-effective biomarker for heart failure (HF)
diagnosis and therapy monitoring [4–6]. The BNP gene encodes a 134-
amino acid preproBNP precursor, which is converted to 108-amino acid
proBNP by the cleavage of a 26-amino acid signal peptide. The processinghinese Hamster Ovary; proBNP,
t failure.
ﬂoor, Joukahaisenkatu 6, Turku,
menov).
The Canadian Society of Clinical Che
al., Searching for a BNP stand
..., Clin Biochem (2016), httpof proBNP gives rise to two fragments: the N-terminal fragment of
proBNP (NT-proBNP, 1–76 aar) and the C-terminal region, biologically
active BNP hormone (77–108 aar) [1,7,8].
There is substantial variety of BNP commercial immunoassays on the
market. Recent comparative studies show there are marked differences
of the measured concentration of BNP obtained on different platforms
[9,10]. Plasma BNP concentrations measured by various immunoassays
differ substantially, complicating interpretation of results and rendering
the cut-off concentration method dependent; especially if patient's
specimens are analyzed by 2 different assays. As a consequence, the re-
sults of BNP measurements obtained by different assays and platforms
can not be compared with reliability. One of the reasons for the lack of
equivalence between existing BNP immunoassays may be the absence
of a common calibrator. Presently, there is no agreement on whichmists.
ard: Glycosylated proBNP as a common calibrator enables improved
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as manufacturers are using different calibrators. Considering this, we
suggested that a common calibratormay reduce the degree of between-
assay variability of existing commercial BNP immunoassays.
It has been shown that apart from bioactive BNP, unprocessed
proBNP glycosylated in N-terminal part, within 1–76 amino acid region
of the molecule, represents a substantial or even major part of BNP
immunoreactivity observed in the plasma of HF patients and healthy
donors [11–14]. One may speculate that the reference material for
BNP immunoassays should be proBNP, the natural and major BNP anti-
gen form found in the circulation. Further, all commercial BNP assays
have been shown to cross-react with the proBNP form, although the ex-
tent of cross-reactivity varies among assays [15,16]. In the current study
we compared 6 BNP-related proteins to determine a form that could be
used as a common calibrator to improve the comparability of commer-
cial BNP immunoassays.
2. Materials and methods
2.1. Plasma collection
Following Institutional Review Board approval, EDTA-plasma sam-
ples were obtained on consent from 20 acute and 20 chronic heart fail-
ure patients at Hennepin County Medical Center, Minneapolis, MN.
Plasma collection was performed in the presence of protease inhibitors
to prevent proteolytic degradation of BNP [17,18]. Brieﬂy, EDTA
vacutainer plastic blood collection tubes were used for plasma collec-
tion. After centrifugation, the samples were immediately transferred
into storage tubes containing benzamidine (Sigma, ﬁnal inhibitor con-
centration 10 mmol/L) and 4-(2-aminomethyl)benzenesulfonyl ﬂuo-
ride hydrochloride (Sigma, ﬁnal inhibitor concentration 5 mmol/L).
2.2. Sample set preparations
71 samples were prepared for measurements of BNP, in duplicate,
by each immunoassay. In addition to the 40 EDTA-plasma samples
from HF patients, 30 samples with 6 external calibrators (5 concentra-
tions for each calibrator) diluted in BNP/proBNP/NT-proBNP-free
EDTA-plasma (HyTest) were prepared. The following external calibra-
tors were used in the study: synthetic BNP (Bachem), recombinant
BNP expressed in Escherichia coli (E. coli) (Raybiotech), recombinant
nonglycosylated proBNP (expressed in E. coli; HyTest), His-tagged (N-
terminal) recombinant nonglycosylated proBNP (expressed in E. coli;
Raybiotech), recombinant glycosylated proBNP (expressed in Human
Embryonic Kidney (HEK) cells; HyTest) and recombinant glycosylated
proBNP (expressed in Chinese Hamster Ovary (CHO) cells). Expression
of proBNP in CHO-S cells (Invitrogen) and puriﬁcation from conditioned
medium was performed as described [14,19]. Calibrators were diluted
in BNP/proBNP/NT-proBNP-free EDTA-plasma to give rise solutions
with 5 different concentrations: 1.17, 0.585, 0.195, 0.065, 0.022 nmol/L,
respectively (equal to 4050, 2025, 675, 225, 75 pg/mL for BNP 1–32, re-
spectively). One blank sample in every set didn't contain anyBNP/proBNP
(BNP/proBNP/NT-proBNP-free plasma). All samples (calibrators and plas-
ma samples) were aliquoted and provided with a set of ready-to-use
encoded probes.
2.3. Deglycosylation of recombinant proBNP
ProBNP derived from HEK and CHO cells were incubated with
a deglycosylation enzyme cocktail consisting of О-glycanase,
sialidase A, β [1–3,4]galactosidase, β [1–4,6]galactosidase and β-N-
acetylhexosaminidase (ProZyme). Reactions were carried out in
10 mM phosphate buffer, pH = 5.0, at 37 °C, for 16 h and stopped by
addition of SDS-PAGE sample buffer, then subjected toWestern blotting
analysis.Please cite this article as: A.G. Semenov, et al., Searching for a BNP stand
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Proteins were separated by Tris-Tricine SDS-PAGE in 16.5% T, 3% C
gel [20]; 1.5 μg of protein per lane was applied. The proteins were after-
wards transferred onto nitrocellulose membrane for Western blotting
analysis [21]. Antibody 15F11 (anti-NT-proBNP, epitope 13–20, HyTest)
was used as primary detection antibody; bands were visualized using
3,3′-diaminobenzidine dihydrochloride.
2.5. BNP measurements
BNP concentrations were measured with ﬁve commercial BNP assays
exactly according to manufacturers' guidelines using appropriate quality
control materials: Alere Triage, Siemens Centaur XP, Abbott I-STAT,
Beckman Access2 (performed at Hennepin County Medical Center, Min-
neapolis, MN) and ET Healthcare Pylon BNP assay (performed at ET
Healthcare). Duplicates of each sample were measured within one run.
Quality control materials were analyzed for all assays along manufac-
turers' guidelines, and found accepted, with %CVs b 13% at approximately
100 ng/L for all assays: Alere Triagewith CV=12.5% (atmean 111 ng/L);
Siemens Centaur XP with CV= 10.1% (at mean 165 ng/L); Abbott I-STAT
with CV= 12.8% (at mean 215 ng/L); Beckman Access 2 with CV= 9.5%
(at mean 145 ng/L), ET Healthcare Pylon BNP assay with CV = 10.2%
(at mean 100 ng/L).
2.6. Calculation of the BNP values with external calibrators
The initial BNP concentrationswere obtained with the internal stan-
dards provided by a manufacturer. Concentrations of two repeats were
averaged. For subsequent calibration of the assayswith the external cal-
ibrators the concentrations of BNP obtained for the samples containing
external calibrators were used to create calibration curves, which were
plotted in logarithmic scale (log-log). The equations obtained with
power-law ﬁtting for every calibrator were used to recalculate the
BNP concentrations in plasma samples.
2.7. Data analysis
The agreement between BNP concentrations measured by different
BNP assays was analyzed for every pair of assays by using Passing-
Bablock regression analysis (XLSTAT 2014) [22]. Coefﬁcients of determi-
nation (R2) were calculated with Microsoft Excel for Mac 2011, version
14.1.0. Between-assay CVs were calculated with Prism 5 for Mac OS X,
version 5.0a, 2007.
3. Results
BNP immunoassays compared in the present study were selected to
represent a variety of antibodies and standards utilized in commercial
BNP immunoassays. Characteristics of the antibodies and BNP standards
utilized in the assays are summarized in Table 1. BNP concentrations
measured in the 40 HF plasma samples differed considerably between
the 5 BNP immunoassays. Up to 3.6-fold differences (1.9-fold mean;
range 0.9 to 3.6) were observed when using immunoassays and their
calibrators provided by manufacturers. As shown in Table 2, the degree
of equivalence was analyzed by Passing-Bablock regression analysis
between results of every pair of BNP immunoassays and similar results
were obtained for ﬁve out of six external calibrators.When glycosylated
proBNP expressed in HEK cells was utilized as a common external cali-
brator for all assays, a signiﬁcant reduction of the between-assay vari-
ability was achieved with regression line slopes close to 0.9–1.0 for
almost every pair of assays. There was a good linear relationship for all
BNP immunoassays and all calibrators, as shown by the coefﬁcient of
determination (R2) values. Almost 2-fold reduction in mean between-
assay CV (%) was observed after recalibrationwith glycosylated proBNPard: Glycosylated proBNP as a common calibrator enables improved
://dx.doi.org/10.1016/j.clinbiochem.2016.11.003
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3A.G. Semenov et al. / Clinical Biochemistry xxx (2016) xxx–xxxexpressed in HEK cells compared to internal calibrators (14.8% vs.
28.9%) (Table 3).
As follows from Fig. 1, the 5 different BNP assays were not equal
in recognition of BNP, nonglycosylated proBNP and glycosylated
proBNP, reﬂecting the differences in cross-reactivity of commercial
BNP immunoassays for different BNP-related forms (BNP compared to
proBNP, glycosylated proBNP compared to nonglycosylated proBNP).
SDS-PAGE analysis followed byWestern blotting of two forms of gly-
cosylated proBNP expressed in HEK cells and CHO cells revealed the dif-
ferences in electrophoreticmobility of these proteins. A lowermobility of
proBNP expressed in HEK cells compared to proBNP expressed in CHO
cells reﬂects a higher extent of O-glycosylation of this protein, since the
treatment with a mix of glycosidases completely diminished the differ-
ence between two forms of recombinant proBNP (Fig. 2).
4. Discussion
Numerous manufacturers currently market BNP immunoassays in-
tegrated in different platforms. Studies suggest that there are marked
differences among the BNP values obtained on different platforms [9,Table 2
Agreement between BNP concentrations measured by different BNP assays with different calib
The equations obtained with Passing-Bablock regression analysis (y = ax + b) and coefﬁcient






Alere Triage/Abbot I-STAT 0.53x + 4.36 0.78x − 5.23 0.81x
R² = 0.99 R² = 0.99 R² =
Beckman Access2/Abbot I-STAT 0.69x + 3.33 0.57x − 1.09 0.56x
R² = 0.98 R² = 0.98 R² =
Beckman Access2/Alere Triage 1.35x − 22.0 0.76x − 6.31 0.71x
R² = 0.98 R² = 0.98 R² =
Beckman Access2/Siemens Centaur XP 1.29x − 3.41 1.07x − 4.29 0.94x
R² = 1.00 R² = 1.00 R² =
ET Healthcare Pylon/Abbot I-STAT 0.93x + 9.33 0.77x + 9.90 0.99x
R² = 0.96 R² = 0.95 R² =
ET Healthcare Pylon/Alere Triage 1.69x − 15.24 0.96x + 11.02 1.20x
R² = 0.94 R² = 0.92 R² =
ET Healthcare Pylon/Beckman Access2 1.29x − 8.7 1.23x + 12.37 1.72x −
R² = 0.93 R² = 0.92 R² =
ET Healthcare Pylon/Siemens Centaur XP 1.65x − 19.09 1.37x + 7.19 1.57x −
R² = 0.94 R² = 0.93 R² =
Siemens Centaur XP/Abbot I-STAT 0.56x + 1.82 0.56x + 1.07 0.63x
R² = 0.99 R² = 0.99 R² =
Siemens Centaur XP/Alere Triage 1.06x − 11.11 0.72x + 1.41 0.78x
R² = 0.99 R² = 0.99 R² =
Please cite this article as: A.G. Semenov, et al., Searching for a BNP stand
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or instrument, such that different results from different assays and
platforms are poorly comparable. Although the current FDA diagnostic
cut-off to exclude acute HF for BNP is set at 100 ng/L, considering the
high substantial differences between different BNP immunoassays we
suggest that more appropriate medical decisions concentrations should
be determined for each individual assay, or that a standard reference
material be used in the calibration of all BNP assays.
Themain causes of non-harmonized BNP assays are a) different epi-
tope speciﬁcities of the capture and detection antibodies used and
b) the lack of a common referencematerial for calibration of BNP assays
by manufacturers. Commercial BNP assays are based on different anti-
bodies and standard materials. Almost all BNP immunoassays employ
two antibodies speciﬁc for two distantly located epitopes of the BNP
peptide chain, directed at either for the intact cysteine ring or for the
N- or C-terminus of the peptide. The only exception used in the
current study was the single-epitope BNP immunoassay (SES-BNP™)
implemented in the platform by ET Healthcare [23]. This assay differs
from conventional sandwich-type BNP assays in that it utilizes one
antibody speciﬁc to the relatively stable ring fragment of the BNP
molecule (epitope 11–17, capture antibody)which is within the biolog-
ically active cysteine ring and a detection antibodywhich recognizes the
immune complex of capture antibody with BNP/proBNP only. Epitope
speciﬁcity is an internal characteristic of immunoassays, which cannot
be inﬂuenced externally. However, one may speculate that a common
calibrator may help to reduce this variability of the BNP concentrations
and achieve a good comparability between BNP concentrations obtain-
ed with different assays.
The great heterogeneity of proBNP-derived peptides circulating in
human blood can partially explain the differences among the results
provided by immunoassay methods considered speciﬁc for BNP [16].
Due to such a high heterogeneity and diversity of circulating BNP-
related peptides, there is no way to prepare a calibrator, which will be
absolutely identical to endogenous BNP. However, considering the
prevalence of glycosylated proBNP as a major BNP-immunoreactive
form, onemight suggest that glycosylated proBNP could serve as a com-
mon calibrator and stable standard for BNP immunoassays.
In the present study we observed that BNP concentrations measured
inHF plasma samples differed considerably between BNP immunoassays.rators.














− 1.89 1.21x − 5.19 1.67x + 24.19 0.44x − 2.47 0.97x − 15.84
0.99 R² = 0.99 R² = 0.99 R² = 0.99 R² = 0.99
+ 5.16 0.62x − 4.84 0.73x − 17.06 0.44x − 3.40 0.87x − 3.03
0.98 R² = 0.98 R² = 0.97 R² = 0.98 R² = 0.98
+ 2.90 0.54x − 22.53 0.45x − 64.64 0.27x − 31.93 0.92x − 3.58
0.99 R² = 0.98 R² = 0.98 R² = 0.98 R² = 0.99
+ 0.41 1.10x − 2.85 1.37x − 6.82 0.84x + 6.89 0.83x − 16.43
1.00 R² = 1.00 R² = 1.00 R² = 1.00 R² = 0.99
− 2.66 1.10x − 19.14 1.16x − 61.91 0.49x − 11.84 1.04x − 7.53
0.96 R² = 0.98 R² = 0.96 R² = 0.96 R² = 0.96
− 0.78 0.88x − 19.60 0.66x − 84.12 0.28x − 18.39 1.04x + 8.20
0.93 R² = 0.94 R² = 0.94 R² = 0.93 R² = 0.93
11.09 1.69x − 5.32 1.58x − 32.06 0.63x + 0.54 1.14x − 1.75
0.94 R² = 0.98 R² = 0.93 R² = 0.93 R² = 0.93
11.41 1.86x − 17.95 2.12x − 44.51 0.88x − 5.04 0.97x − 24.38
0.94 R² = 0.93 R² = 0.93 R² = 0.93 R² = 0.94
+ 3.44 0.58x − 4.65 0.54x − 14.16 0.85x − 9.92 1.07x + 11.24
0.99 R² = 0.99 R² = 0.98 R² = 0.99 R² = 0.99
+ 1.88 0.50x − 10.35 0.34x − 39.18 0.53x − 41.10 1.09x + 19.76
0.99 R² = 0.99 R² = 0.98 R² = 0.99 R² = 0.99
ard: Glycosylated proBNP as a common calibrator enables improved
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Table 3
Equivalence of 5 commercial BNP assays (Alere Triage, Siemens Centaur XP, Abbott I-STAT,
BeckmanAccess2 and ETHealthcare Pylon BNP) calculated as themean between-assay CV
(%) for internal calibrators and 6 external calibrators.
Calibrator Mean between-assay CV (%) (SD)
Internal calibrators 28.9 (4.8)
Synthetic BNP 27.4 (4.3)
Recombinant BNP 24.5 (4.4)
Nonglycosylated proBNP 33.1 (5.9)
His-tagged nonglycosylated proBNP 47.2 (11.1)
Glycosylated proBNP (CHO) 36.2 (5.9)
Glycosylated proBNP (HEK) 14.8 (6.5)
Fig. 2.Western blot analysis of puriﬁed proBNP expressed in HEK and CHO cells. Samples
of recombinant proBNPs (1.5 μg/lane) were treated with either a deglycosylation cocktail
(G) or buffer alone (B) for 16 h. Immunostaining was performed with anti-NT-proBNP
antibodies 15F11 (epitope 13–20).
4 A.G. Semenov et al. / Clinical Biochemistry xxx (2016) xxx–xxxThis conﬁrmed the lack of equivalence of BNP immunoassay measure-
ments observed in previous studies. We assessed 6 candidate BNP-
related calibrators for their suitability to reduce between-assay variation.
Synthetic and recombinant BNPs were compared with recombinant
nonglycosylated proBNPs from 2 different vendors and glycosylated
proBNPs expressed in 2 different mammalian cell lines. According to
our ﬁndings, among 6 tested calibrators, glycosylated proBNP expressed
inHEK cells taken as a common calibrator enabled improved comparabil-
ity of BNP immunoassays concentrations, as conﬁrmed by signiﬁcant re-
duction of between-assay CV from 28.9% for internal calibrators to
14.8% for glycosylated proBNP expressed in HEK cells.
Two forms of recombinant proBNP, nonglycosylated (produced in
E. coli) and glycosylated (produced in mammalian cells, HEK and
CHO) were compared in this study. These two forms of proBNP differ
in their N-terminal part, which is glycosylated for proBNP expressed
in HEK and CHO cells and nonglycosylated for proBNP expressed in
E. coli [8,14,19]. One may expected that the BNP concentrations obtain-
ed after recalculation should be similar for both forms of proBNP,
nonglycosylated and glycosylated, since the BNP-part of bothmolecules
is the same (non-modiﬁed by glycosidic residues). However, this was
not the case. Glycosylated and nonglycosylated proBNPs showed very
different results in reduction of between-assay variability and exhibited
different immunoeactivity. Additionally, two forms of glycosylated
proBNP expressed in HEK and CHO cells were not similar, as one mayFig. 1. Relative measured concentrations of human synthetic BNP, recombinant nonglycosyla
proBNP (HEK cells) and recombinant glycosylated proBNP (CHO cells) measured with Alere Tr
assays. The data are expressed as percentage of measured concentration obtained for recom
each calibrator) were averaged (±SD).
Please cite this article as: A.G. Semenov, et al., Searching for a BNP stand
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the inﬂuence of O-glycosylation on the recognition of proBNP by anti-
bodies utilized in the assays. The differences in the level of glycosylation
of proBNP expressed in HEK and CHO cells follow from the results of
SDS-PAGE analysis and have also been previously shown [19]. The ex-
tent of glycosylation and the structure of attached glycosidic residues
probably interfere with the recognition of proBNP by antibodies, due
to the steric hindrance of the glycosidic residues. This may explain the
reason why different proBNP forms taken as a common calibrators ex-
hibited different results in harmonization of BNP results.
An important characteristic of a calibrator is stability. Glycosylat-
ed proBNP expressed in HEK cells was shown to have a high stability
in plasma samples, fulﬁlling the requirement of robust stability [24–
26]. The stability of glycosylation pattern of recombinant proBNP
expressed in HEK cells upon storage is additionally conﬁrmed by
the observation that the results obtained in the present study areted proBNP, recombinant His-tagged nonglycosylated proBNP, recombinant glycosylated
iage, Siemens Centaur XP, Abbott I-STAT, Beckman Access2 and ET Healthcare Pylon BNP
binant BNP. The ratios of values for 4 measurements (0.585, 0.195, 0.065, 0.022 nM for
ard: Glycosylated proBNP as a common calibrator enables improved
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5A.G. Semenov et al. / Clinical Biochemistry xxx (2016) xxx–xxxin a good accordance with those obtained in our preliminary study:
the same batch of proBNP which was kept for 1.5 years at −70 °C
was used in both studies.
It should be noted that there are some limitations to the present
study. First, only one batch of recombinant proBNP expressed in HEK
cells has been tested and no batch-to-batch variation has been evaluat-
ed. Given the pronounced effect of the extent of glycosylation on reduc-
tion of inter-assay variability, the low variability of the glycosylation
pattern of recombinant glycosylated proBNP is expected to be an essen-
tial characteristic for a protein suggested as a common calibrator for
BNP immunoassays.
The extent of glycosylation of proBNP expressed in HEK cells is
reproducible in different preparations of recombinant proBNP, as
conﬁrmed by the analysis of recognition by antibodies speciﬁc for the
regions of proBNP modiﬁed by glycosidic residues in a quality control
procedure. The lot-to-lot variations do not exceed on average 10%.
Further, one may speculate that the positive effect of glycosylated
proBNP expressed in HEK cells is caused not by its glycosylation, but
rather by the presence of some contaminations in protein prepara-
tion. Although this assumption can not be completely excluded, the
effect of glycosylation on proBNP recognition by antibodies has been
conﬁrmed in previous studies showing different degree of cross-
reactivity of commercial BNP assays to glycosylated and nonglycosylated
proBNP [15,16]. Also the different effect on reduction of between-assay
variability of proBNPs expressed in HEK and CHO cells with different
extent of glycosylation, may indicate that the effect on reduction of
between-assay variability observed in the present study is caused by
glycosylation.
Presently, there is no primary referencematerial and no primary ref-
erence measurement procedure for BNP measurements. The current
study demonstrates that harmonization of commercial BNP immunoas-
says is technically possible. Among assessed 6 different candidate
calibrators for their suitability to reduce between-assay variation, glyco-
sylated proBNP (expressed in HEK cells) taken as a common calibrator
enables signiﬁcantly improved comparability of BNP immunoassays re-
sults. These data suggest that glycosylated proBNP expressed in HEK
cells has a potential to become a reference material that may allow
standardization of BNP measurement results. Future studies need to
better deﬁne our promising preliminary observations.
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